Percheron TherapeuticsPERCF -0.18% 3-Year ROIIC % is 372.83 as of Jun. 2025. The stock has 2 warning signs investors should review. Among 941 Drug Manufacturers companies, Percheron Therapeutics ranks better than 96.81% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Percheron Therapeutics's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 372.83%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Percheron Therapeutics's 3-Year ROIIC % or its related term are showing as below:
PERCF's 3-Year ROIIC % is ranked better than 96.81% of 941
companies
in the Drug Manufacturers industry
Industry Median: 3.7
vs PERCF: 372.83
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Percheron Therapeutics 3-Year ROIIC % Related Terms
Percheron Therapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Percheron Therapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Percheron Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Percheron Therapeutics 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Percheron Therapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Percheron Therapeutics's 3-Year ROIIC % falls into.
Percheron Therapeutics's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -10.878 (Jun. 2025) - -5.349 (Jun. 2022) )
/
( 0.144 (Jun. 2025) - 1.871 (Jun. 2022) )
=
-5.529
/
-1.727
=
320.15%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Percheron Therapeutics (PERCF) has a 3-Year ROIIC % of 372.83 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Percheron Therapeutics and its competitors. According to the industry distribution chart, Percheron Therapeutics ranks #30 out of 941 companies in the Drug Manufacturers industry, placing it in the top 3.2%.
Is Percheron Therapeutics' 3-Year ROIIC % too high?
Percheron Therapeutics' current 3-Year ROIIC % is 372.83. The Drug Manufacturers industry median 3-Year ROIIC % is 3.70. Percheron Therapeutics' value of 372.83 is 9976.5% above this industry median. Based on the distribution chart, Percheron Therapeutics ranks #30 out of 941 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Percheron Therapeutics' 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Percheron Therapeutics ranks #30 out of 941 companies for 3-Year ROIIC %. This places Percheron Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.70. Percheron Therapeutics' value of 372.83 is 9976.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.70, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Percheron Therapeutics's current 3-Year ROIIC % of 372.83 is 9976.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Percheron Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Percheron Therapeutics's current 3-Year ROIIC % is 372.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Percheron Therapeutics stock overvalued right now?
Percheron Therapeutics (PERCF) has a current 3-Year ROIIC % of 372.83. The current 3-Year ROIIC % is 372.83 and 9976.5% above the Drug Manufacturers industry median of 3.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Percheron Therapeutics (PERCF), the current 3-Year ROIIC % is 372.83 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PERCF has been successfully added to your 